Related Experiment Video
Updated: Aug 25, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate Cancer Imaging with 18F-Fluciclovine
Bital Savir-Baruch1, David M Schuster2
1Department of Medical Imaging, Division of Nuclear Medicine, University of Arizona, Banner University Medical Center-Tucson, 1501 N. Campbell, Tucson, AZ 85724, USA; Department of Radiology, Loyola University Chicago Stritch School of Medicine, 2160 S 1st Avenue, Maywood, IL 60153, USA.
Abstract:
18F-Fluciclovine PET is approved for the evaluation of patients with suspected prostate cancer recurrence. 18F-Fluciclovine PET is highly specific for the localization of extraprostatic disease even with negative conventional images and low prostate-specific antigen and has been reported to influence patients' management and improve outcome. With the recent Food and Drug Administration approval of prostate-specific membrane antigen (PSMA) PET, 18F-Fluciclovine is likely to be used as an adjunct modality in patients with suspected occult local recurrence and/or negative PSMA findings.
More Related Videos
Related Concept Videos
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies V: Intravenous Urography and Retrograde Pyelography

